These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34970502)

  • 1. Corrigendum: Real-World Lenvatinib
    Kuo YH; Lu SN; Chen YY; Kee KM; Yen YH; Hung CH; Hu TH; Chen CH; Wang JH
    Front Oncol; 2021; 11():823960. PubMed ID: 34970502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Lenvatinib
    Kuo YH; Lu SN; Chen YY; Kee KM; Yen YH; Hung CH; Hu TH; Chen CH; Wang JH
    Front Oncol; 2021; 11():737767. PubMed ID: 34760699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis.
    Choi NR; Kim JY; Hong JH; Hur MH; Cho H; Park MK; Kim J; Lee YB; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    BMC Gastroenterol; 2022 Mar; 22(1):135. PubMed ID: 35337274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting.
    Fukushima T; Morimoto M; Ueno M; Kubota K; Uojima H; Hidaka H; Chuma M; Numata K; Tsuruya K; Hirose S; Kagawa T; Hattori N; Watanabe T; Matsunaga K; Yamamoto K; Tanaka K; Maeda S
    JGH Open; 2022 Jan; 6(1):29-35. PubMed ID: 35071785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy.
    Burgio V; Iavarone M; Di Costanzo GG; Marra F; Lonardi S; Tamburini E; Piscaglia F; Masi G; Celsa C; Foschi FG; Silletta M; Amoruso DC; Rimini M; Bruccoleri M; Tortora R; Campani C; Soldà C; Viola MG; Forgione A; Conti F; Salani F; Catanese S; Giacchetto CM; Fulgenzi C; Coppola C; Lampertico P; Pellino A; Rancatore G; Cabibbo G; Ratti F; Pedica F; Della Corte A; Colombo M; De Cobelli F; Aldrighetti L; Cascinu S; Casadei-Gardini A
    Cancer Manag Res; 2021; 13():9379-9389. PubMed ID: 34992463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma.
    Terashima T; Yamashita T; Takata N; Toyama T; Shimakami T; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
    Hepatol Res; 2020 Jul; 50(7):871-884. PubMed ID: 32307874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population.
    Lee SW; Yang SS; Lien HC; Peng YC; Ko CW; Lee TY
    J Clin Med; 2022 Mar; 11(5):. PubMed ID: 35268535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study.
    Rimini M; Shimose S; Lonardi S; Tada T; Masi G; Iwamoto H; Lai E; Burgio V; Hiraoka A; Ishikawa T; Soldà C; Shirono T; Vivaldi C; Takaguchi K; Shimada N; Astara G; Koga H; Nouso K; Joko K; Torimura T; Hiasa Y; Salani F; Scartozzi M; Cascinu S; Casadei-Gardini A
    Hepatol Res; 2021 Dec; 51(12):1229-1241. PubMed ID: 34591334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis.
    Nakano M; Kuromatsu R; Niizeki T; Okamura S; Iwamoto H; Shimose S; Shirono T; Noda Y; Kamachi N; Koga H; Torimura T;
    Hepatol Commun; 2020 Aug; 4(8):1218-1228. PubMed ID: 32766480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
    Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario.
    Dipasquale A; Marinello A; Santoro A
    J Hepatocell Carcinoma; 2021; 8():241-251. PubMed ID: 33884259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis.
    Chen S; Shi M; Shen L; Qi H; Wan W; Cao F; Xie L; Wu Y; Chen G; Mo J; Zhu G; Ye D; Zhang Y; Feng Z; Xu L; Fan W
    Int J Hyperthermia; 2020; 37(1):384-391. PubMed ID: 32323585
    [No Abstract]   [Full Text] [Related]  

  • 13. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.
    Xue M; Wu Y; Zhu B; Zou X; Fan W; Li J
    Am J Cancer Res; 2021; 11(12):6107-6118. PubMed ID: 35018245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study.
    Lee J; Han JW; Sung PS; Lee SK; Yang H; Nam HC; Yoo SH; Lee HL; Kim HY; Lee SW; Kwon JH; Jang JW; Kim CW; Nam SW; Oh JS; Chun HJ; Bae SH; Choi JY; Yoon SK
    J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.
    Chen SC; Huang YH; Chen MH; Hung YP; Lee RC; Shao YY; Chao Y
    BMC Cancer; 2022 Jan; 22(1):55. PubMed ID: 35016637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Facciorusso A; Tartaglia N; Villani R; Serviddio G; Ramai D; Mohan BP; Chandan S; Abd El Aziz MA; Evangelista J; Cotsoglou C; Ambrosi A
    Am J Transl Res; 2021; 13(4):2379-2387. PubMed ID: 34017396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Camrelizumab Plus Sorafenib
    Liu Q; You N; Li J; Wu K; Peng X; Wang Z; Wang L; Zhu Y; Zheng L
    Front Oncol; 2021; 11():694409. PubMed ID: 34737945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis.
    Casadei-Gardini A; Scartozzi M; Tada T; Yoo C; Shimose S; Masi G; Lonardi S; Frassineti LG; Nicola S; Piscaglia F; Kumada T; Kim HD; Koga H; Vivaldi C; Soldà C; Hiraoka A; Bang Y; Atsukawa M; Torimura T; Tsuj K; Itobayashi E; Toyoda H; Fukunishi S; Rimassa L; Rimini M; Cascinu S; Cucchetti A
    Liver Int; 2021 Jun; 41(6):1389-1397. PubMed ID: 33547848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.